CD163 and cancer: We have evaluated 16 studies that used macrophage/monocyte markers in PMDs and cancer [43,44,46,48,49,51,52,53,54,63,64,65,66,67,68,69] using antibodies against CD68 (pan-MΦ), CD86, CD80 (both M1-MΦ), CD163 and CD204 (both M2-MΦ), and CD14 (monocyte/macrophage marker).